NL-OMON33530已完成不适用
A FIRST-IN-HUMAN SINGLE-DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF LY2165766 INCLUDING BRAIN DOPAMINE D2 RECEPTOR OCCUPANCY BY POSITRON EMISSION TOMOGRAPHY (PET) - LY2165766 SDSS/PET study
Chorus LRL (devisie van Eli Lilly)0 个研究点目标入组 38 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male
- •Part A: 18 - 65 year.
- •Part B: 35 - 65 year
- •Part C: 35 - 65 year
排除标准
- •Relevant disease in medical history
研究者
相似试验
已完成
不适用
A first-in-human single-dose escalation study of the safety, pharmacokinetics and pharmacodynamics of the test drug including brain Serotonin Receptor Transporter (SERT) occupancy by Positron Emission Tomography (PET).NL-OMON34991Eli Lilly38
已完成
不适用
A First in Human, Single-dose Escalation Study of LY2562175 In Healthy Subjectslipidsmetabolism10013317NL-OMON33901Chorus, Lilly Research Laboratories18
进行中（未招募）
1 期
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CRelapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CTIS2023-504403-92-00Janssen - Cilag International200
进行中（未招募）
1 期
A study of JNJ-79635322 in participants with relapsed or refractory multiple myeloma or previously treated amyloid light-chain (AL) amyloidosisRelapsed or refractory multiple myeloma or previously treated amyloid light-chain (AL) amyloidosisCancerISRCTN13185938Janssen Research & Development, LLC140
尚未招募
不适用
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myelomamultiple myelomaNL-OMON53500Janssen-Cilag12